FDA Takes Unprecedented Action on CBD Market
The U.S. Food and Drug Administration has announced a major enforcement initiative targeting the largely unregulated cannabidiol (CBD) market, issuing warning letters to 78 companies and flagging over 200 individual products sold online for significant violations. The action represents the agency's most aggressive move yet to bring order to a market that has grown to an estimated $7.5 billion annually with minimal regulatory oversight.
What Triggered the Crackdown
The enforcement action follows a comprehensive FDA survey of CBD products available through major online retailers and direct-to-consumer websites. The survey, conducted between October 2025 and February 2026, tested 300 products and found alarming rates of noncompliance with labeling and safety standards.
- 52% of products contained significantly more or less CBD than stated on the label
- 28% contained detectable levels of THC above the 0.3% legal threshold
- 15% were contaminated with heavy metals, pesticides, or residual solvents
- 71% made health claims that violate federal regulations regarding dietary supplements and unapproved drugs
Unproven Health Claims Under Fire
A central focus of the enforcement action is the proliferation of unsubstantiated health claims. Products were found claiming to cure or treat cancer, Alzheimer's disease, epilepsy, chronic pain, anxiety, and dozens of other conditions without any FDA-approved evidence supporting these assertions.
Consumers deserve to know that what is on the label matches what is in the product, and that health claims are supported by evidence. The current state of the CBD market fails on both counts, and that is unacceptable from a public health perspective. — FDA Commissioner Dr. Robert Califf
The FDA emphasized that while Epidiolex (cannabidiol) has been approved as a prescription medication for certain seizure disorders, no other CBD products have received FDA approval for any medical use. Companies marketing CBD as a treatment for serious diseases are not only violating the law but potentially causing harm by encouraging consumers to forgo proven treatments.
Impact on Major Online Retailers
The enforcement action extends beyond individual CBD brands to the platforms that sell them. The FDA has sent formal notifications to Amazon, Walmart, and several other major online retailers requesting voluntary removal of products that make illegal health claims or fail to meet labeling standards. While these platforms have internal policies regarding CBD products, enforcement has been inconsistent.
Amazon, which officially prohibits the sale of CBD-infused products, acknowledged that some items have evaded its detection systems and stated it would work with the FDA to identify and remove noncompliant listings.
What This Means for Consumers
For the estimated 60 million Americans who have used CBD products, the FDA's findings underscore the importance of careful product selection. Until comprehensive federal regulation is established, consumers face a marketplace where quality varies enormously between products and brands.
The FDA recommends that consumers:
- Look for products that provide certificates of analysis from independent third-party laboratories
- Be skeptical of products making dramatic health claims
- Choose products from companies that clearly label CBD content, ingredients, and sourcing
- Consult with a healthcare provider before using CBD products, especially alongside prescription medications
- Report adverse events to the FDA's MedWatch program
The Regulatory Path Forward
The enforcement action comes as Congress continues to debate a comprehensive regulatory framework for CBD. Several bills have been introduced that would establish CBD as a regulated dietary supplement with mandatory testing, labeling, and manufacturing standards. Industry groups have largely supported federal regulation, arguing that clear rules would benefit responsible companies while eliminating bad actors.
Until legislation passes, the FDA has indicated it will continue using its existing enforcement authorities to target the most egregious violations, with particular focus on products that pose direct safety risks or make claims related to serious diseases. Companies that received warning letters have 15 business days to respond with corrective action plans or face potential legal consequences including product seizure and injunctions.
